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D4
+ T cell responses are critical for durable control of viral replication in chronic infections 1, 2 . Virus-specific CD4 + T cell immunity is of particular interest for HIV infection, which is characterized by functional impairment and destruction of CD4 + T cells. While classical models divided CD4 + T cells into distinct lineages, studies have demonstrated the importance of CD4 + T cell plasticity 3 . Persistent antigen and inflammatory signals cause impairment of antigen-specific responses, a state called immune exhaustion. Virus-specific CD8 + T cell exhaustion has been extensively investigated 4 and represents a bona fide cell differentiation program. These studies highlighted the relevance of genome-wide transcriptional studies to understand T cell impairment 5 .
Compared with CD8
+ T cells, less is known on CD4 + T cell dysfunction. Murine lymphocytic choriomeningitis virus (LCMV)-specific CD4 + T cells in chronic infection, while exhibiting some characteristics shared with CD8
+ T cells, also present distinct features 6, 7 , including loss of a T H 1 signature 5 and skewing towards a T FH phenotype 8, 9 . Whether findings in mice can be extrapolated to HIV infection in humans is unclear. Some features of virus-specific CD4 + T cells are shared between both infections: upregulation of co-inhibitory receptors are found in HIV progressors with ongoing viremia (chronic progressors) and chronic LCMV infection 5, 10 . Rare subjects who spontaneously suppress HIV (elite controllers) frequently exhibit robust virus-specific T H 1 responses 11 and strong proliferative capacity, similarly to mice infected with the acute strain of LCMV. However, HIV and LCMV are distinct viruses and there are notable differences between species in terms of T cell differentiation mechanisms, such as T FH generation 12 . An issue of critical clinical relevance is the lack of restoration of effective anti-HIV immunity after suppressive ART: viral rebound is the rule after cessation of therapy. Whether persistent HIV-specific CD4 + T cell dysfunction on ART contributes to this failed response is an important, yet unresolved, question. The paucity of experimental tools capable of identifying highly heterogeneous antigen-specific CD4
+ T cells has hampered the study of HIV-specific CD4 + T cell help. Intracellular cytokine staining (ICS) assays are of limited sensitivity for many non-T H 1 effector functions, and the use of HLA class II tetramers in humans is constrained by availability, requirement for pre-defined epitopes and genetic diversity.
To determine key pathways and molecules that link HIV-specific T cell help to viral control, we here performed genome-wide transcriptional analyses and functional assays of HIV-specific CD4 + T cells from HIV-infected humans with diverse viral loads before ART initiation and followed a subgroup of them longitudinally after viral suppression on therapy.
Results
Links between HIV-specific CD4
+ transcriptome profiles and viremia. To define molecular features that discriminate HIVspecific CD4
+ T cells in progressive versus controlled infection, we performed a cross-sectional study of 38 chronically infected people who were untreated at the time of sampling. These included 'elite controllers' (ECs, HIV plasma viral load <50 viral RNA (vRNA) copies ml between 50 and 5,000 copies ml -1 ) and 'chronic progressors' (CPs, viral load ≥5,000 copies ml -1 ) (for participant characteristics see Supplementary Table 1) .
We utilized an activation-induced marker (AIM) assay to identify CD4 + T cells specific for the Gag protein (hereafter, termed HIV-specific CD4 + T cells). Ex vivo stimulated HIV-specific CD4 + T cells were identified by the co-upregulation of CD40L and CD69 on their surface after a 9-h stimulation with an HIV Gag peptide pool 13 ( Fig. 1a and Supplementary Fig. 1a ). Combining two markers enhanced detection of HIV-specific CD4 + T cells by reducing background compared to CD40L alone ( Supplementary Fig. 1b,c) . This AIM assay overcomes limitations of cytokine-based techniques for detection of virus-specific cells, allows live-cell sorting and captures a broader antigen-specific CD4
+ T cell population ( Supplementary Fig. 1d ). There was no significant difference in the magnitude of HIV-specific CD4
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CD40L
+ Gag-specific CD4 + T cells among the CP, VC and EC groups by Kruskal-Wallis test. Horizontal lines and bars represent median and ±interquartile range, respectively (n = 11 CPs, 11 VCs, 13 ECs). c, Paired volcano plot comparisons depicting DEGs as measured by microarray analysis of sorted HIV-specific CD4 + T cells in the three groups. Red, pink and blue dots represent DEG with log 2 |fold change (FC)| > 1 and P adj < 0.05, log 2 |FC| > 1 or P adj < 0.05, respectively. A two-sided moderated t-test followed by the Benjamini-Hochberg method correction was applied (n = 11 CPs, 9 VCs, 12 ECs). d, Euler diagrams of DEG between each pairwise comparison of the three groups of participants (log 2 FC > 1, P < 0.05); numbers represent DEGs. e, Top significant enriched gene ontology terms from the curated C5 MSigDB via two-sided CAMERA analysis. Blue, red and white color denote negative, positive or not significant (as defined by FDR < 0.05 by the Benjamini-Hochberg method), respectively. cohorts or correlation with viremia or CD4 count ( Fig. 1b and Supplementary Fig. 1e,f) .
We reasoned that the AIM assay could reveal the transcriptome modulation in response to cognate antigen-mediated TCR signaling, reflecting the functional state of CD4 + T cells. We thus performed microarray analysis of sorted ex vivo stimulated HIVspecific CD4
+ T cells. Pairwise comparisons between cohorts (Fig. 1c) EC  CP  EC  CP  EC  CP  EC  CP   IL17F   CXCL11   IL22   IL17A   CXCL10   CXCL9   IL26   SOCS2   CXCL13   IL1B   IL23R  LTB   CCL20   IL9   IL13   CD274  CCL5  SOCS1   IL2   LAMP3   CD109   LAG3   GZMB   TIGIT   CD84   SOCS3   IL10RA   GPR183   IFNg   IRF1   TOX   CD200   SLAMF6   IL5   BATF3   - . c, T FH signature: GSE50391 (CXCR5 high CD45RO versus CXCR5 neg tonsil samples). d, LCMV exhaustion signature GSE41866 (LCMV Clone 13 D30 versus Armstrong D30-Exhausted versus Memory). Two-sided P value by CAMERA and FDR by Benjamini-Hochberg method. The arrows beneath the barcode plots depict the orientation of the enrichment between CP and EC. e-h, Heat maps of mRNA expression of the top 50 significant genes of each CD4 + T cell signature in CPs and ECs. Red and blue font of gene names denote upregulated and downregulated mRNA expression in CPs versus ECs, respectively. i, PCA representation of CPs (n = 11), VCs (n = 9) and ECs (n = 12) on the basis of transcriptional expression of 90 genes associated with CD4 + T cell differentiation, effector functions and exhaustion. Transcriptional expression (−∆Ct values) was evaluated by RT-qPCR (Fluidigm). The top 35 contributing genes are displayed and color-coded according to their contribution. Bigger dots represent the mean PC coordinates for each group. The numbers in parentheses stand for the percentage of variance that the PC accounts for. j, Correlation of PC1 values for each individual with viral load by two-tailed Spearman correlation (n = 11 CPs, 9 VCs, 12 ECs).
between all three cohorts, with extensive dissimilarities between CPs and ECs. Fewer transcriptional differences were detected between the VC and EC groups. The majority of DEGs between VCs and ECs were also observed in the CPs versus ECs comparison (Fig. 1d ). CPs and VCs showed the fewest DEGs, suggesting that viremia strongly impacts the transcriptional landscape of HIV-specific CD4 + T cells. We next used CAMERA (correlation adjusted mean rank gene set test) 14 enrichment analysis to investigate molecular mechanisms underlying HIV-specific T help alterations associated with disease status. We compared the identified DEGs to the Molecular Signatures Database (MSigDB) C5 collection of curated gene sets, which comprises the gene ontology (GO) terms associated with biological processes, molecular functions and cellular components (Fig. 1e) . The 'Positive regulation of T helper cell differentiation' signature was negatively associated with viremia. Consistently, the 'Positive regulation of CD4 + αβ T cell activation' and 'Regulation of leukocyte migration' gene sets were significantly under-represented in CPs compared with both VCs and ECs, contrasting with upregulation of the MHC class II protein complex in CPs. Expression of genes associated with protein transport and/or processing was reduced in CPs. The pathways enriched with viremia included processes associated with chromatin modification, mitotic cell cycle, DNA packaging, chromosome segregation, response to stress and apoptosis.
This approach identifies potential pathways associated with HIV-specific CD4 + T cell dysfunction, and points to a central role for altered T cell differentiation, regulation and activation in this impairment.
HIV-specific CD4
+ polarization is associated with disease status. Given the potential role for altered T cell differentiation in HIVspecific CD4
+ T cell impairment, we determined features of CD4 + T cell differentiation associated with disease status. Using CAMERA we compared our sets of DEGs with human helper T polarization signatures from the C7 collection in the MSigDB and publicly available microarray datasets. While the different conditions used in the generation of these signatures (for example, activated versus unactivated cells) may complicate the interpretation of such associations, we observed notable differences among cohorts. Compared with CPs, ECs and VCs displayed enriched T H 1 and T H 17 signatures [15] [16] [17] (Fig. 2a,b ,e,f, Supplementary Fig. 2a and Supplementary  Tables 2-4) . Cardinal genes associated with T H 17 cell differentiation and function were upregulated in ECs (Fig. 2f) . In viremic people (CPs, VCs), we noted a striking enrichment of a T FH signature 18 ( Fig. 2c,g and Supplementary Fig. 2a ) compared with ECs. There was congruent upregulation of several key T FH -associated genes compared with ECs, with the notable exception of BCL6, which was instead upregulated in ECs (Fig. 2g and Supplementary Table 5) . Although we did not observe a statistically significant enrichment of a LCMV-specific CD4 + T cell exhaustion signature 5 in CPs compared with ECs ( Fig. 2d ) (which might be due at least in part to the methodological differences), several of the DEGs enriched in CPs were well-known exhaustion-associated genes ( Fig. 2h and Supplementary Table 6 ). Several interferon-stimulated genes upregulated in the LCMV model of exhaustion, such as IFH1, IFIT3 and IFI44, were upregulated in ECs.
We next used real-time quantitative reverse transcription PCR (RT-qPCR) to further quantify levels of key DEGs identified by microarrays and selected additional CD4 + T cell genes. Principal component analysis (PCA) discriminated CPs from ECs, whereas there was more overlap between CPs and VCs (Fig. 2i) . PC1 values significantly inversely correlated with viremia, showing that changes in the CD4 + T cell profile relate to antigen load (Fig. 2j) . The RT-qPCR data were consistent with the microarray results (Supplementary Table 7 ). They confirmed that genes associated with T FH functions and B cell help (CXCL13, SLAMF6, CD84) and exhaustion (TIGIT, CD200, LAG3, TOX) were enriched in CPs. This contrasted with genes related to T H 17 and T H 22 functions (IL17F, IL22) and the interferon-induced chemokines (CXCL9, CXCL10, CXCL11), which were enriched in ECs (Fig. 2i) . Expression of selected transcription factors was consistent with these observations ( Supplementary Fig. 2b ): ECs expressed significantly more TBX21 and AHR genes, respectively coding for T H 1 and T H 22 master transcription factors, and in ECs there was a trend for enhanced expression of RORC, a master transcription factor of T H 17 differentiation. The behavior of the master T FH transcription factor BCL6 contrasted to most T FH -associated genes: BCL6 was significantly upregulated in ECs compared to CPs in contrast to MAF, another transcription factor critical for T FH differentiation, which was highly expressed in CPs. Helios (IKZF2), a transcription factor overexpressed in LCMV-specific CD4 + T cells in chronic infection, was also upregulated in CPs compared to ECs. Examining correlations between gene expression revealed positive and negative associations of genes, many not anticipated by classical dichotomic models of T H differentiation. These results are consistent with a complex spectrum of differentiation and functional profiles of HIV-specific CD4 + T cells ( Supplementary Fig. 2c,d ). These data show higher expression of a T FH -like signature in HIV-specific CD4 + T cells in progressive infection, contrasting with enriched T H 1 and T H 17 signatures in subjects achieving spontaneous viral control.
Upregulation of classical T FH -associated genes in CXCR5 neg HIV-specific CD4
+ of CPs. We next investigated whether the enrichment of the T FH signature in HIV-specific CD4 + T cells of CPs compared to ECs was due to a higher fraction of HIV-specific circulating T FH cells (cT FH ). We used the CD69/CD40L AIM assay to assess the percentages of HIV-specific CXCR5 +
CD45RA
-memory CD4 T cells (CXCR5 mem ) in both cohorts ( Fig. 3a and Supplementary  Fig. 3a,b) . As PD-1 expression on HIV-specific CD4 + T cells correlates with viremia 19 , PD-1 was omitted as a T FH marker to avoid bias towards CPs. We observed only a trend for higher fractions of HIVspecific CXCR5 mem in CPs than in ECs, with considerable overlap between groups (Fig. 3b) . In contrast, single-subject gene set enrichment analysis (ssGSEA) scores showed a significant enrichment of the T FH signature in CPs compared with ECs (Fig. 3c) , consistent with the cohort-based CAMERA analyses shown in Fig. 2c,g (Fig. 3d ). These data suggest that differences in percentage of CXCR5 mem alone are not sufficient to explain the markedly enriched T FH signature observed in HIV-specific CD4 + T cells of CPs. To define the cell subsets that contributed to the T FH transcriptional signature observed in CPs, we applied microarray analysis to paired live-sorted subsets of CXCR5 mem and CXCR5 neg HIV-specific CD4 + T cells from CPs and ECs ( Fig. 3e ; gating strategy in Supplementary Fig. 3a ). CXCR5 mRNA expression was consistent with protein expression (Fig. 3h) . Differences in gene expression between CPs and ECs were more significant in the CXCR5 neg than in the CXCR5 mem subsets of HIV-specific CD4 + T cells (Fig. 3e ). CPs displayed a marked enrichment of the T FH signature not only in the CXCR5 mem compartment, but also in the CXCR5 neg HIV-specific CD4 + T cell subset (Fig. 3f) . We confirmed expression of several markers classically associated with T FH cells in CXCR5 mem and CXCR5 neg HIV-specific CD4
+ T cells at the mRNA level by RT-qPCR or at the protein level by flow cytometry. Consistent with the microarray results, upregulation of the TCR co-receptors PD-1, TIGIT, CD200 and ICOS on CXCR5 neg HIV-specific CD4 + T cells clearly differentiated CPs from ECs ( Fig. 3g and Supplementary Fig. 3c ). Surface markers SLAMF6 and CD84 (both associated with help to B cells) and BTLA (highly expressed in T FH cells; Fig. 3h ) were significantly higher in CXCR5 neg CD4
+ T cells of CPs compared with ECs, while the mRNA expression of BCL6 and TCF7 did not differ in CXCR5 neg CD4
+ T cells between the two groups. Transcriptional expression of PRDM1 and MAF was significantly higher in CXCR5 neg CD4
+ T cells of CPs compared with ECs ( Fig. 3i ). In contrast to ECs, CXCR5 expression in CPs did not clearly delineate cells with a T FH transcriptional profile: ICOS, SLAMF6, BTLA, CD84, TIGIT, CD200 and the T FH -associated transcription factor MAF mRNA levels in CXCR5 neg cells were equal or even superior to their CXCR5 mem autologous counterparts ( Fig. 3g-i and Supplementary Fig. 3c ). These data demonstrate the atypical upregulation of the 'T FH -like' signature in the CXCR5 neg HIV-specific CD4 + T cells of CPs compared with ECs.
Robust expression of T FH cytokines in CXCR5 neg HIV-specific CD4
+ of CPs. We next sought to elucidate if the enriched T FH signature in CXCR5 mem and CXCR5 neg HIV-specific CD4 + T cells of CPs compared to ECs is congruent with the enhancement of some T FH functions, and to determine the phenotype of these effector cells. We assessed mRNA expression of the T FH cytokines CXCL13 and IL-21 at single-cell resolution using a sensitive flow cytometric RNA fluorescent in situ hybridization (RNA-flow-FISH) technique, as previously described 20, 21 . This assay is superior to standard ICS for detection of IL-21-producing cells 20 . There were increased frequencies of CXCL13 mRNA + and IL21 mRNA + HIV-specific CD4 + T cells in CPs compared to ECs (Fig. 4a,b ). This was a distinct feature of HIV-specific responses, as the expression after stimulation with the superantigen staphylococcal enterotoxin B (SEB) was similar in both cohorts ( Fig. 4c ) and cytomegalovirus (CMV) pp65-specific CD4 + T cells expressed less CXCL13 and IL21 than HIV-specific CD4 + T cells in paired comparisons within the same humans ( Supplementary Fig. 4a ). As CD40L is not expressed on all antigen-specific CD4 + T cells on activation, we confirmed that the differential expression of CXCL13 and IL21 between CPs and ECs holds true without combining the RNA-flow-FISH and AIM assays and without pre-gating on CD40L
+ cells ( Supplementary  Fig. 4b- 
i). Largely distinct CD4
+ T cell populations produced CXCL13 and IL21 mRNAs at the time point examined (Fig. 4d,e) . We confirmed the increased CXCL13 production in CPs compared with ECs at the protein level by measuring CXCL13 concentration by ELISA in the supernatant of CD8-depleted peripheral blood mononuclear cells (PBMCs) after a 48-h stimulation with HIV Gag ( Supplementary Fig. 5a ). CXCL13
+ and IL21 + cells expressed high levels of CXCR5 protein compared with total HIV-specific CD4 + T cells in ECs. In contrast, the levels of CXCR5 expression on CXCL13
+ and IL21 + cell were comparable to the total population in CPs (Fig. 4f ). This gain of T FH -like functions by CXCR5 neg HIV-specific CD4 + T cell in CPs was further apparent when we compared the ratios of IL21 + and CXCL13 + responses between the CXCR5 mem and CXCR5 neg subsets (Fig. 4g ). As the inhibitory receptors PD-1 and TIGIT are markers of T FH cells 12 , and may also be associated with exhaustion, we examined their expression on CXCL13 mRNA + and IL21 mRNA + HIV-specific CD4 + T cells. The majority of these cytokine-expressing cells were PD-1 + /TIGIT + , particularly in CPs (Fig. 4h,i and Supplementary Fig. 5b,c) . Thus, the expression patterns of the inhibitory co-receptors PD-1 and TIGIT were consistent with T FH skewing and may not imply exhaustion of these responses.
Finally, we explored possible links between HIV-specific CD4 + T cell help and antibody responses. We assessed plasma levels of p24-specific antibodies by ELISA and biolayer interferometry binding analysis. The results obtained by the two methods were highly correlated ( Supplementary Fig. 5d ). Although p24-specific antibody concentrations in the CP and EC groups were similar overall ( Fig. 4j ), we observed a significant correlation between the magnitude of HIV-specific CD4 + T cell responses and p24-specific antibodies, which was maintained when only the CP group was considered (Fig. 4k) . There was no significant association between CXCR5 mem responses and p24-specific antibodies (Fig. 4l) . However, there was a significant correlation between CXCR5 neg HIV-specific CD4 + T cell frequencies and antibody responses in CPs, but not ECs (Fig. 4m) , which might suggest that the CXCR5 neg subset has helper T function to B cells in vivo.
These data demonstrate that dysregulated CXCR5 neg HIVspecific CD4 + T cells in progressive infection gain functions and phenotypic features classically attributed to T FH cells.
Mucosal immunity-related cytokines in HIV-specific CD4
+ of ECs. As we observed an enriched T H 17 signature in HIV-specific CD4 + T cells in ECs compared to CPs, we characterized the expression of IL-17F and IL-22 at the single-cell level. RNA-flow-FISH enabled superior detection of these cytokines in HIV-specific CD4 + T cells compared with ICS (Fig. 5a,b) . We observed more robust IL17F and IL22 HIV-specific CD4 + T cell responses in ECs compared with CPs (Fig. 5c ). In contrast, IL17F and IL22 expression patterns in SEBor CMV-activated CD4 + T cells did not differ between the groups ( Fig. 5d and Supplementary Fig. 4a ). We confirmed the strong IL-17F, IL-22 and IL-17A secretion by HIV-specific CD4 + T cells in ECs at the protein level, in contrast to low or undetectable production in CPs (Fig. 5e and Supplementary Fig. 5e-g ).
The IL17F mRNA + and IL22 mRNA + subsets constituted two partially overlapping, but mostly distinct, cell populations (Fig. 5f,g ). In both CPs and ECs, these cells preferentially expressed CCR6, a chemokine receptor critical for recruitment of T H 17 and T H 22 cells to mucosal tissues (Fig. 5h) . Expression of CXCR3, a marker of T H 1 cells also expressed on CD4
+ T cells with mixed T H 1 and T H 17 properties that are expanded in some inflammatory diseases 17 , was low on IL17F and IL22 mRNA + of both CPs and ECs ( Fig. 5i and Supplementary Fig. 5h ). Performing the RNA-flow-FISH without the AIM assay and CD40L
+ pre-gating showed again contrasting patterns of IL17F and IL22 expression between CPs and ECs ( Supplementary Fig. 4b-i) .
Systemic translocation of microbial products plays a critical role in immune activation related to HIV pathogenesis 22 . Loss of gut mucosal integrity and T H 17 cell depletion have been associated with immune activation and disease progression 23 . We thus investigated possible links between HIV-specific T H 17 and T H 22 responses and systemic immune activation. We observed an inverse correlation between IL22 mRNA expression by HIV-specific CD4
+ T cells and co-expression of the activation markers HLA-DR and CD38 on total CD4
+ and CD8 + T cells ( Fig. 5j and Supplementary Fig. 5i ). We identified similar associations for IL17F (Fig. 5k and Supplementary  Fig. 5j ). We next investigated the relationship between preservation of IL17 + and/or IL22 + HIV-specific CD4 + T cells and microbial translocation by deep sequencing of cell-free RNA fragments in plasma-a reflection of the part of the body's microbiome that can access the circulation, the majority of which resides in the gut. The total levels of bacterial RNA reads in plasma did not significantly differ between the groups of CPs, ECs and uninfected control donors (UDs) (Fig. 5l) . However, we observed a lower plasma bacterial RNA species diversity in CPs compared to the EC and UD groups (Fig. 5m) . These observations may reflect low gut microbiome diversity, a state associated with systemic inflammation in several diseases 24 ( Supplementary Fig. 5k, l) . IL22 and IL17F transcription in HIV-specific CD4 + T cells was significantly correlated with bacterial RNA species diversity (Fig. 5n,o) . CPs and ECs qualitatively differed in the bacterial RNA profile, forming largely distinct clusters (Supplementary Fig. 5m ). IL22 and IL17F mRNA + levels in HIV-specific CD4 + T cells inversely correlated with the prevalence of Proteobacteria, a phylum of Gram-negative bacteria that is increased in the gut microbiome in HIV-infected people 25 and has been proposed as a marker of dysbiosis 26 ( Fig. 5p,q) . Thus, robust IL22 + and IL17F + HIV-specific CD4 + T cells can be detected in the blood of ECs, while these responses are severely impaired in CPs. Associations of these deficiencies with systemic immune activation, reduced plasma bacterial RNA species diversity and a skewing towards greater Proteobacteria abundance, suggest that these findings in blood reflect perturbed gut homeostasis and a loss of protective mucosal immunity.
ART results in a distinct transcriptome of HIV-specific CD4
+ . Finally, we sought to determine whether the observed HIVspecific CD4
+ T cell profiles were the consequences of ongoing viral antigen exposure, or the results of durable cell-fate decision programs that would persist after viral suppression on ART. We longitudinally followed a subgroup of eight CPs and analyzed a second sample obtained while on ART (for participant characteristics see Supplementary Table 8 ). Pairwise comparisons between the EC, CP pre-ART (CPpre) and CP post-ART (CPpost) cohorts (Fig. 6a,b) showed sets of DEGs between all three groups, with fewer differences in the CPpre versus CPpost and CPpost versus EC than the CPpre versus EC comparison, as might be expected. We next focused on selected GO terms and gene signatures that were identified as differentially expressed between CPs and ECs in Figs. 1 and 2 . While initiation of ART in CPs modulated the activity of several pathways regulating apoptosis and gene expression towards the levels observed in EC, differences in the 'Positive regulation of T helper cell differentiation' , 'Positive regulation of CD4 + αβ T cell activation' and 'Regulation of leukocyte migration' persisted (Fig. 6c) . We therefore examined how ART affected helper T polarization signatures. Expression of the T FH signature in HIV-specific CD4 + T cells was markedly reduced by ART, to levels similar to that found in ECs (Fig. 6d) , while expression of the T H 1, T H 17 and LCMV exhaustion signatures was little affected by therapy: the differences clearly persisted between CPpost and EC (Fig.  6e,f and Supplementary Fig. 6a ). Expression of selected individual genes of interest was also consistent with these findings when expression levels in EC were considered as references (Fig. 6g,  Supplementary Fig. 6b and Supplementary Tables 9 and 10 ). While the results should be considered as trends, given the limited size of the cohorts, expression of some genes appeared corrected by ART (for example, CXCL13), whereas others are not restored (for example, IL22).
These data demonstrate that suppressive ART results in a transcriptional landscape of HIV-specific CD4 + T cells distinct from the profiles of both untreated CPs and ECs. We identified gene modules susceptible to manipulation of antigen load, while others were unresponsive to antiviral therapy alone.
Discussion
The molecular features of virus-specific CD4 + T cells associated with pathogen containment are poorly understood in chronic human infections. We used genome-wide transcriptional analyses following ex vivo stimulation with HIV antigen to uncover differences in HIV-specific CD4 + T cell differentiation and function in chronically infected humans with various viremia levels. An atypical enrichment of a T FH -like signature in CXCR5 neg HIV-specific CD4 + T cells characterized progressive infection. In contrast, elite control of viral replication was associated with robust HIV-specific T H 22 and T H 17 responses, which correlated negatively with immune activation and correlated positively with a greater diversity of bacterial RNA species in plasma and lower Proteobacteria abundance. None of these differences were detected in SEB or CMV pp65-reactive cells, revealing antigen-specific TCR signaling-driven processes. Suppressive ART in chronic progressors elicited a distinct HIV-specific CD4 + T cell transcriptome, revealing, in comparison to elite controllers, the presence of viremia-sensitive (for example, T FH signature) and viremia-unresponsive (for example, T H 1, T H 17 and T H 22 signatures) gene modules. These data suggest that HIVspecific CD4
+ T cell dysregulation does not represent a mere loss of helper T functions, as classically defined for immune exhaustion, but an adaptation to environmental cues combined with persistent changes, likely resulting from durable cell-fate decision programs.
At first sight, the marked T FH signature 18 identified in CPs contrasts with the murine LCMV model, in which T FH responses in chronic infection are critical for delayed viral control 8 . The extraordinary ability of HIV to generate escape mutations and elude autologous antibody neutralization likely contributes to these opposite associations between T FH differentiation and disease outcome. A study showed that T FH cells in chronic LCMV infection are capable of supporting generation of neutralizing antibody effective against the contemporaneous virus 9 . In contrast, the immune system lags behind the evolution of autologous HIV strains 27 . Kinetics of viral evolution in HIV infection may thus overcome the ability of adaptive T FH skewing to contribute to delayed viral control. While technical limitations have so far hampered investigation of HIV-specific germinal center T FH in lymph nodes, robust expansion of total germinal center T FH populations was demonstrated in viremic HIVinfected people and simian immunodeficiency virus (SIV)-infected macaques, albeit with qualitative defects [28] [29] [30] [31] . Genes classically associated with T FH cells that are enriched in the CXCR5 neg HIV-specific CD4 + T cells of CPs include IL21 and CXCL13. HIV p24-specific antibody titers in plasma correlated with frequencies of CXCR5 neg HIV-specific CD4 + T cells, suggesting that these responses may provide help to B cells in vivo. Studies in murine models have shown that CXCR5 −/− CD4 + T cells are able to take over some helper B functions 32, 33 , resulting in the generation of low-affinity binding antibodies 9 . Acquisition of T FH -like properties by CXCR5 neg CD4
+ T cells has also been reported in rheumatoid arthritis 34 and cancer 35 and combines B help function with migration to inflamed tissues. These analogies suggest shared pathways of CD4 + T cell differentiation between diverse diseases associated with chronic inflammation.
Damage to the gut mucosa with associated microbial translocation 22 and increased inflammatory properties of the enteric microbiota 36 are major drivers of HIV-associated chronic inflammation. We observed that HIV-specific T H 17 and T H 22 responses were abundant in ECs and rare in CPs. IL-17F and IL-17A are closely related cytokines recruiting neutrophils to sites of inflammation. IL-22 promotes intestinal barrier function 37 and supports complement-mediated elimination of pathobionts 38 . .
Together with the analysis of bacterial RNA fragments in plasma, these CD4 + T cell data suggest that studies of peripheral blood can provide useful insight into the systemic consequences of perturbed gut homeostasis. Probiotic and IL-21 therapy in ART-treated SIV-infected macaques was associated with enhanced polyfunctional T H 17 expansion and reduced markers of microbial translocation and dysbiosis compared to ART alone 42 . It will be important to determine whether such interventions restore HIV-specific CD4 + T cell profiles. This work raises questions that will need to be addressed in further studies. AIM assays require activation to enable cell identification. While we believe that analyzing the transcriptional profile modulated by TCR signaling is highly relevant for analysis of T cell responses, it will be important to investigate other populations of HIV-specific CD4 + T cells that do not co-upregulate CD69 and CD40L, for example, by other AIM markers or by tetramers. Experiments in animal models will be required to define the ontogeny of CXCR5 neg CD4 + T cells with T FH -like features and whether they transitioned through a bona fide T FH stage during their development. Longitudinal studies from the time of acute infection may identify events in the genesis or persistence of HIV-specific CD4 + T cell dysregulation. Investigations of human gut and lymph node biopsies, while challenging, would define the relationships between features of HIV-specific CD4 + T cells in blood and other anatomical compartments.
In summary, this work identifies extensive alterations in HIVspecific CD4 + T cell transcriptional profiles and demonstrates that SLAMF6  CD84  BCL6  TCF7  POU2AF1  MAF  IL22  IL17A  IL17F  CCR6  IL23R  AHR  RORC  IL2  IFNG  TNF  GZMB  CXCR3  TBX21 transcriptome datasets available on pathogen-specific CD4 + T cells in humans, our results will also provide useful benchmark comparisons for other infectious diseases and vaccine-induced responses.
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Methods
Participants and samples. Leukaphereses were obtained from study participants at the Montreal General Hospital, Montreal, Canada; at the Centre Hospitalier de l'Université de Montréal, Montreal, Canada; and at Massachusetts General Hospital, Boston, USA. The study was approved by the respective institutional review boards, written informed consent obtained from all participants before enrollment and PBMC samples obtained by leukapheresis. Samples were collected between 2013 and 2018. Subject characteristics are summarized in Supplementary  Table 1 . 'Chronic progressors' (CPs) were defined as people with a viral load of more than 5,000 vRNA copies per ml of plasma; 'viremic controllers' (VCs) were defined as people with more than 50 and less than 5,000 vRNA per ml plasma; and 'elite controllers' (ECs) were defined as subjects who spontaneously controlled viremia to below 50 RNA copies per ml plasma in the absence of therapy. CPs, VCs and ECs were either treatment naïve or untreated for at least 3 months. Eight CPs were followed longitudinally and a second sample was obtained at least 6 months after initiation of ART therapy and suppression of viral loads below 50 copies ml -1 (Supplementary Table 8 ). PBMCs were isolated by the Ficoll density gradient method and stored in liquid nitrogen.
Antibodies. For details of antibodies used, see Supplementary Tables 11-20 and descriptions of use below. In all cases, antibodies are monoclonal and raised in mice unless otherwise stated. All antibodies are commercially available, were validated by the suppliers and titrated using biological and/or isotype controls. . Following a 9-h stimulation, the cells were stained for 30 min at 4 °C before live-cell sorting on a FACS Aria cell sorter (BD BioSciences) equipped for handling of biohazardous material. Two panels of antibodies were used to isolate live-cells subsets according to combinations of surface markers. In the first panel for isolation of total CD69 +
CD40L
+ Gag-specific CD4 + T cells, PBMCs were stained as indicated in Supplementary Table 11 . The gating strategy for cell sorting is illustrated in Supplementary Fig. 1 . In the second panel used for isolation of CXCR5 mem and CXCR5 neg subsets of CD69 + CD40L + Gag-specific CD4 + T cells, PBMCs were stained as indicated in Supplementary Table 12 . The gating strategy for cell sorting is illustrated in Supplementary Fig. 3 . The FACS Aria was operated at 70 pounds per square inch with a 70-μm nozzle. For all populations, 5,000 cells were collected directly into RLT lysis buffer (Qiagen).
Phenotyping of Gag-specific CD4 + T cells identified by the CD69/CD40L AIM assay. PBMCs were thawed and plated in 24-well plates at 10 × 10 6 cells ml -1 in RPMI + 10% HAB Serum (HAB) and rested for 3 h at 37 °C. Before stimulation, CD40 blocking antibody was added directly into culture at a final concentration of 0.5 μg ml ). Cells were stimulated for 9 h, collected and stained for 30 min at 4 °C with the antibodies in Supplementary  Table 13 . Cells were washed, fixed for 20 min in 2% paraformaldehyde, washed and resuspended in 1% FCS/PBS for flow acquisition on a five-laser LSR II flow cytometer (BD BioSciences).
Phenotyping of immune activation markers. PBMCs were thawed and rested overnight at 37 °C. The next day, cells were washed and stained with viability dye (20 min at 4 °C) and surface markers (20 min at 4 °C) (Supplementary Table 14) . Fluorescence minus one staining was used to define the cut-off for positivity. Cells were washed, fixed for 1 h in 2% paraformaldehyde, washed and resuspended in 1% FCS/PBS for flow acquisition on a five-laser LSR II flow cytometer (BD BioSciences).
Standard ICS for cytokine measurements. PBMCs were incubated for 6 h with an HIV Gag peptide pool at a concentration of 0.5 μg ml -1 per peptide in the presence of 2.5 µg ml −1 brefeldin A (BD GolgiPlug) and (0.3 µl ml ) monensin (BD GolgiStop). For delayed ICS assays, 2.5 µg ml −1 brefeldin A (BD GolgiPlug) and (0.3 µl ml ) monensin (BD GolgiStop) were added 9 h after stimulation with the Gag peptide pool, and cells were cultured for an additional 12 h. Unstimulated cells were used as negative control and SEB (0.5 µg ml Gene expression analysis. Whole-transcriptome analysis by microarrays. Total RNA was purified using the RNeasy Plus Micro Kit (Qiagen). RNA integrity was assessed using a 2100 Bioanalyzer (Agilent Technologies). Sense-strand complementary DNA was synthesized from total RNA using a fixed volume of 3 µl. Fragmentation and labeling were performed to produce single strand DNA (ssDNA) with the Applied Biosystems GeneChip WT Pico Terminal Labeling Kit according to manufacturer's instructions (Applied Biosystems). After fragmentation and labeling, 5 µg DNA target was hybridized on GeneChip Clariom D, human (ThermoFisher Scientific) and incubated at 45 °C in the Genechip Hybridization oven 640 (Affymetrix) for 17 h at 60 r.p.m. GeneChips were then washed in a GeneChips Fluidics Station 450 (Affymetrix) using Applied Biosystems Hybridization Wash and Stain kit according to the manufacturer's instructions (Applied Biosystems). The microarrays were finally scanned on a GeneChip scanner 3000 (Affymetrix).
Validation of transcriptional expression by Fluidigm. Total RNA was purified using the RNeasy Plus Micro Kit (Qiagen). cDNA was synthesized using all RNA available (or 1-5 ng) with the High-Capacity Reverse Transcription Kit with RNase Inhibitor (Life Technologies) (25 °C for 10 min, 37 °C for 120 min, 85 °C for 5 min). cDNA equivalent to 1,000 sorted cells was subjected to gene-specific preamplification using TaqMan . For experiments evaluating mRNA expression without CD40 blocking antibody, PBMCs were stimulated for 12 h. After stimulation, cells were stained with a viability dye (20 min, 4 °C, Fixable LiveDead, eBioscience) and then surface markers were labeled (30 min, 4 °C) with antibodies (see panels in Supplementary Tables  17-20) . Samples were next subjected to the PrimeFlow RNA assay (Affymetrix/ eBioscience/ThermoFisher) for specific mRNA detection as per manufacturer's instructions. All buffers and fixation reagents were provided with the kit, with the exception of flow cytometry staining buffer (2% FBS/PBS). After fixation and permeabilization, cytokine/chemokine mRNAs were labeled with sets of probe pairs, as listed in Supplementary Tables 17-20 . The probes were diluted 1:5 in diluent and hybridized to the target mRNA for 2 h at 40 °C. Samples were washed to remove excess probes and stored overnight in the presence of RNAsin. Signal amplification was achieved as previously described 20 by sequential 1.5-h, 40 °C incubations with the preamplification and amplification mix. Amplified mRNA was labeled with fluorescently tagged probes for 1 h at 40 °C. A negative control probe and a positive control probe (against house-keeping gene RPL13A) were included in each experiment. Gates were set on the unstimulated control where appropriate or scrambled probes. Samples were acquired on an LSR II (BD Bioscience) or a BD LSRFortessa (experiments without CD40 blocking antibody). Analysis was performed using FlowJo (Treestar, v.10) and SPICE v.5.35 software.
Measurements of cytokine secretion by beads arrays and ELISA. One million CD8 T cell-depleted PBMCs (Dynabeads CD8, StemCell) were incubated with an HIV Gag peptide pool (1 μg ml -1 per peptide) or left unstimulated and incubated at 37 °C in RPMI supplemented with 10% HAB and Pen-Strep. Cytokine secretion in supernatants was measured 48 h after stimulation on a Luminex beads array platform, as previously described 19, 20 . Measurements were performed in duplicates using the Human High Sensitivity Cytokine Premixed Kit B (R&D Systems) for IL-17A and IL-22 or for IL-17F on a Bio-plex 200 array system (Bio-Rad Laboratories) as per manufacturer's instructions. CXCL13 was measured separately with the Human CXCL13 Quantikine ELISA Kit (R&D Systems), as per manufacturer's instructions.
Measurement of p24-specific antibodies by ELISA. The anti-p24 ELISA was performed as follows: 96-well plates (Thermo Scientific Nunc, FluoroNunc/ LumiNunc, MaxiSorp Surface) were coated with 0.1 µg ml −1 of recombinant p24 (NIH, catalog no. 12028) or BSA (Bioshop, catalog no. ALB001.100) in PBS overnight at 4 °C. Plates were blocked for 90 min at room temperature (RT) with blocking buffer (TBS, Tween 0.1%, BSA 2%) and then washed four times with washing buffer (TBS, Tween 0.1%). Dilutions of human sera (1/1,000, 1/3,000, 1/6,000) or rabbit anti-HIV p24 antiserum (NIH, catalog no. 4250) in washing buffer containing 0.1% of BSA were incubated for 2 h at RT. Plates were washed four times with washing buffer before incubation for 90 min at RT with HRPconjugated secondary antibodies: goat anti-human IgG HRP (Invitrogen, catalog no. 31413) or anti-IgG rabbit HRP (Invitrogen, catalog no. 31462). Plates were then washed four times with washing buffer before revealing with standard enhanced chemiluminescence reagent (Perkin Elmer, NEL105001EA) with a TriStar luminometer (LB 941, Berthold Technologies).
Plasma microbiome sequencing. Circulating total RNA and DNA were isolated from frozen plasma using RNAzolBD (MRCgene) according to the manufacturer's recommendations. After RNA fragmentation and reverse transcription using random hexamers, the obtained transcripts, as well as the isolated plasma DNA, were individually incorporated into barcoded cDNA libraries on the basis of the Illumina TruSeq platform. Libraries were validated by microelectrophoresis, quantified, pooled and clustered on Illumina patterned flow cells. Clustered flow cells were sequenced on an Illumina HiSeq 4000 in 75-base paired reads.
Gene expression data analysis. Microarrays. The preprocessing of the microarray data was done in R (v.3.3.3, ref. 43 ) using the oligo package (v.1.38.0, ref. 44 ). Specifically, the CEL files were loaded in R and the rma function was applied for background subtraction, normalization and summarization. Quality control was performed by inspecting various diagnostic plots of the intensity distribution and correlation structure of control and regular probes. After review of the QC plots, three outliers were removed. Combat (sva package v.3.30.1) has been applied for batch normalization of samples using four replicates as reference for the normalization. The normalized data were used for the subsequent subanalyses CPpre versus EC, CPpre versus CPpost and CPpost versus EC.
Differential expression. Differential analysis of gene expression was done by the R package limma 45 . Using the lmFit function, a linear model was fit to each gene separately. Moderated t-tests were performed between each group. P values were adjusted using the Benjamini-Hochberg method for multiple test correction.
CAMERA. T H 1 signature (GSE59295; T H 1 versus T H 2) was available in the C7 collection of MSigDB. The T H 17 signature (GSE49703; T H 17 versus T H 1), T FH signature (GSE50391; CXCR5high CD45RO versus CXCR5 − tonsil samples) and LCMV exhaustion signature (GSE41866; LCMV Clone 13 D30 versus Armstrong D30-Exhausted versus Memory) were created using the GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/geo2r/). For each signature, a gene-set test was performed using the camera function from the limma package, accounting for intergene correlation.
Venn diagrams were created using the online tool Eulerr.co (R package v.4.1.0, https://cran.r-project.org/package=eulerr) 46 . Unsupervised hierarchical clustering was performed using the in heatmap2 function in R 43 on relative signal intensity values applying the Euclidean distance metric and complete linkage clustering method. Barcode plots were generated with the barcodeplot function from the limma package.
RT-qPCR results. Analysis of the RT-qPCR data obtained on the microfluidic platform was carried out using GenEx software (MultiD Analyses: http://www. multid.se). Five endogenous control genes were included in the Fluidigm run and the stability of endogenous control genes across all experimental samples was evaluated applying the NormFinder algorithm 47 in GenEx. The mean expression of the most stable endogenous control genes was used for normalization and calculation of −∆Ct values. PCA, biplots and correlograms were created using the prcomp, fviz_pca_biplot and corrplot functions, respectively, in R programming language.
Statistical analyses of flow cytometry, beads array and RT-qPCR results.
Statistical analyses were performed using Prism v.6.0 (GraphPad) using nonparametric tests. Two-group comparisons were performed using the MannWhitney U-test and pairwise comparisons were performed using the Wilcoxon matched-pair test. For comparisons between three groups, Kruskal-Wallis or Friedman one-way analysis of variance with Dunn's post-test was used.
Permutation test (10,000 permutations) was applied for pie-chart comparison using the SPICE software. For correlations, Spearman's R correlation coefficient was applied. Statistical tests were two-sided and P < 0.05 were considered significant.
Bioinformatic analysis of deep-sequencing results of cell-free RNA fragments in plasma. Raw, paired-end Illumina reads were first trimmed for low quality bases and adapter contamination with Trimmomatic 48 . As a first pass to remove hostderived sequences, trimmed reads were first aligned against the HG38 genome with Bowtie 2 (ref. 49 ) and then aligned to HG38 transcriptome with the splice aware aligner, STAR 50 . Unaligned paired-end reads were then assembled into contigs using Trinity 51 . Trinity contigs were then aligned against HG38 again to further remove host-derived sequences with BLAST + (ref.
52
). Remaining contigs were then aligned against the NCBI nucleotide database 53 and quantified with Salmon 54 . Taxonomic information was assigned for each contig and TPM values were collapsed at the species level for each sample for downstream analysis. TPM values for each sample were collapsed on the genus taxonomic level and MorisitaHorn dissimilarity indexes were calculated on a pairwise basis using the R package vegan 55 . The pairwise dissimilarity matrix was then clustered and the heat map was produced with gplots 56 .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Microarray data generated during the current study were deposited in the Gene Expression Omnibus public depository with the accession number GSE128297 for the SuperSeries, and the following accession numbers for the Subseries: GSE129872 (HIV-specific CD4 + T cells samples from CPs, VCs and ECs), GSE128280 (CXCR5mem and CXCR5neg HIV-specific CD4 + T cells from CPs and ECs), GSE128296 (HIV-specific CD4 + T cells samples from CPs before/after ART and ECs). mRNA expression data by high-throughput RT-qPCR are available in the Supplementary Material. All the datasets that support the findings of this study are available from the corresponding author upon reasonable request. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Gene expression data analysis was performed in R v3.3.3 using the following packages and functions: oligo package v1.38.0, the rma function, the limma package (functions lmFit, camera, barcodeplot), the packages gplots, factominer, factoextra and functions heatmap2, prcomp, fviz_pca_biplot and corrplot. For longitudinal ART samples, Combat (sva package 3.30.1) has been applied for batch normalization of samples using 4 replicates as reference for the normalization. Venn diagrams were created using Eulerr.co, (R package version 4.1.0, https://cran.r-project.org/package=eulerr). Analysis of publicly available transcriptomic data was performed by GEO2R online tool (https://www.ncbi.nlm.nih.gov/geo/geo2r/). Analysis of the high throughput qRT-PCR data was carried out using Fluidigm PCR Analysis software v1.4.2. and the GenEx v6 software (MultiD Analyses, URL: http://www.multid.se). Statistical analyses were performed with Prism v6 for Windows (Graphpad Software Inc). Flow cytometry data were analyzed with Flowjo v10 (Treestar) and SPICE 5.35 software (https://niaid.github.io/spice/ For bioinformatic analysis of deep sequencing results of cell-free RNA fragments the following softwares and packages were used: Trimmomatic, Bowtie 2, STAR, Trinity, BLAST+, Salmon, R packages vegan and gplots. Biolayer Interferometry (BLI) binding analysis was performed with ForteBio analysis software version 7.1 (ForteBio).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Microarray data generated during the current study were deposited in the Gene Expression Omnibus (GEO) public depository with the accession numbers GSE (pending) (Figures 1,2,3, 6 and Supplementary Figures 2 and 6 ). mRNA expression data by high-throughput qRT-PCR are available in Supplementary Material (Supplementary Figures 2,3,4) . Supplementary tables 3,4,5,6,7,9 and 10 display the partial raw data of microarray and qRT-PCR. All the datasets that support the findings of this study are available from the corresponding author on reasonable request .
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Sample size
Power calculations for genome-wide transcriptional analyses are difficult to standardize. We therefore used two methods to calculate an approximative number of subjects who would be needed: i) power calculations on published results of lymphocyte transcriptome in subjects with divergent disease outcome (Barwick et al, Nature Immunology 2016), which suggested that 6-8 individuals per group would be sufficient; and ii) power calculations based on qRT-PCR data we have generated on selected genes (e.g, cMAF in HIV-specific CD4 T cells in CP vs EC subjects, also suggesting that 8 subjects per group would be sufficient to detect genes with a >3 fold difference in expression, should they follow a comparable distribution.
Data exclusions From the 40 subjects initially identified for sorting of HIV-specific CD4 T cell responses for the transcriptome analyses, two were excluded because of high background (>0.2%) and/or percentages of CD69+CD40L+ CD4+ Gag-specific T cell responses that were less than three-fold the No Ag condition on the sample identified for sorting. Amongst the studied 38 subjects, the yield of RNA was not sufficient for one subject to run both the microarrays and the high-throughput qRT-PCR arrays (Fluidigm). Three samples didn't pass the QC control of microarrays and therefore 34 individuals were included in the final transcriptome analyses.
Replication
Selected key genes identified in the microarray analyses were validated by different techniques, including: i) high-throughput qRT-PCR arrays (Fluidigm); ii) standard ICS; iii) RNA FLow FISH; and iv) Luminex beads arrays. Furthermore, the qRT-PCR arrays (Fluidigm) were repeated on different chips and with a different organization of the gene probes on the chips. The duplicate results showed high consistency.
Randomization Randomization was not relevant to our observational study. By design, we identified groups of study subjects based on clinical parameters (primarily, HIV viral load in the absence of therapy).
Blinding
Data generation/collection and analysis was blinded to the operator for the different discovery experiments . These include the generation of the microarray data and initial analysis, the detection of p24-specific antibodies by ELISA and Biolayer Interferometry (BLI) binding analysis and plasma RNA microbiome sequencing.
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